Avanafil is a selective phosphodiesterase-5 (PDE-5) inhibitor for the treatment of erectile dysfunction (ED), by inhibiting the PDE-5 enzyme, which is primarily found in the corpus cavernosum of the penis.
Avanafil is known for its rapid onset of action, with effects observed as early as 15 minutes after administration. Common adverse effects include headache, flushing, nasopharyngitis, nasal congestion, and back pain.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | Avanafil, STENDRA, Spedra, TA-1790 |
|---|---|
| IUPAC Name | 4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide |
| CAS | 330784-47-9 |
| Molecular Weight | 483.9 |
| Molecular Formula | C23H26ClN7O3 |
| SMILES | COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCC[C@H]4CO)Cl |